Experts in health economics, pricing and reimbursement
From the outset, health technology companies need to integrate health economics and health outcomes research in their product development strategy to ensure a focus on the market and maximise reimbursement, funding, uptake and market access at launch and beyond.
PHMR is an international team of highly qualified health economists and research scientists that offer expert advice based on extensive experience in HEOR and PR&MA groups in Global, EU and Emerging markets.
Our multidisciplinary approach brings a wealth of experience from health economics, health outcomes, epidemiology, pricing, reimbursement and market access allowing project teams to be assembled that address our clients’ project needs in a flexible and cost efficient manner.
PHMR offers a range of services including:
Provision of strategic advice
Evaluation of existing evidence and recommendations on other evidence needed
Information and analysis to support pricing decisions and positioning options
Communication and publications for market preparation and support
Mark Ratcliffe PhD
Managing Director and P&MA Specialist
Mark Ratcliffe founded PHMR Associates in 2007. Prior to this he had 14 years' experience with major international pharmaceutical companies, in health economics, pricing reimbursement and epidemiology roles: including Group Director, Global Health Economics, Pricing, Reimbursement and Access Strategy for SmithKlineBeecham and Executive Director for PR&A and HE for the EMEA region at Eli Lilly.
He led the pricing strategy and policy development for product launches across numerous therapy areas and has in-depth knowledge of international country pricing systems. He has worked closely with US, European and international markets on operational issues (e.g. PPRS, trade monitoring) and on the implementation of regional policies and strategies.
Prior to joining the pharmaceuticals industry he had a successful career in academia culminating in a Senior Research Fellow position at the London School of Economics. During his academic career Mark consulted extensively to the European Union and its various members states on health, pharmaceutical and Medtech policy. He has over 70 publications to his name and still writes regularly for the international financial and economic press on matters of welfare economics.
Mark has a PhD from the University of Hamburg in Mathematical Economics and Econometrics, an MSc from the London School of Economics in Health Planning and Financing Systems and a BSc in Economics from the University of London. Mark holds a Visiting Research Fellow position at the London School of Economics and teaches on the Master of Advanced Studies in Pharmaceutical Economics and Policy at the University of Lausanne.